Three ways to work with the FDA for better patient-focused trials
Putting patients at the center of drug development allows us to design more efficient clinical trials that yield better data about a product’s risks and benefits. Companies that collaborate with the FDA can get direct feedback on their methodology and help build consensus on patient-relevant outcomes that might be accepted as proof of efficacy and safety.
This article covers three useful practices for getting the most out of your collaboration.
Related Insights
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Webinar
Accelerate global drug development: Leveraging China regulatory changes
Aug 15, 2025
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Article
Implementing patient-centric decentralized clinical trials in Japan
Mar 16, 2023
Related Insights
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Webinar
Accelerate global drug development: Leveraging China regulatory changes
Aug 15, 2025
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Article
Implementing patient-centric decentralized clinical trials in Japan
Mar 16, 2023